Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study

Christophe Pomel (1) , Gwenaël Ferron (2) , Gérard Lorimier (3) , Annie Rey (4) , Catherine Lhomme (4) , Jean Marc Classe (5) , J.M. Bereder (6) , François Quenet (7) , Pierre Meeus (8) , Frederic Marshall (9) , Philippe Morice (4) , Dominique Elias (4)

1 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
2 Institut Claudius Regaud
3 CRLCC Paul Papin - CRLCC - Centre Paul Papin
4 IGR - Institut Gustave Roussy
5 Centre René Gauducheau(Nantes)
6 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
7 CRLC Val d'Aurelle-Paul Lamarque
8 Centre Léon Bérard [Lyon]
9 CAV - Centre Alexis Vautrin

The aim of the present study was to prospectively evaluate morbidity of intra-peritoneal hyper-thermic chemotherapy (HIPEC) using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma and, secondly, to study peritoneal recurrence.

Mots clés: Medicine

Christophe Pomel, Gwenaël Ferron, Gérard Lorimier, Annie Rey, Catherine Lhomme, et al.. Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. EJSO - European Journal of Surgical Oncology, 2010, 36 (6), pp.589. ⟨10.1016/j.ejso.2010.04.005⟩. ⟨hal-00599226⟩